BioAtla Inc

Research BioAtla Inc (BCAB) on Bullrun: market cap USD 6.35M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerBCAB
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 6.35M
• Financial periodFY2025
• Net incomeUSD 59.60M

Valuation Snapshot

latest market cap is USD 6.35M.

About BioAtla Inc

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma.

Frequently asked questions

What is BioAtla Inc's market cap?

BioAtla Inc's market capitalization is USD 6.35M.

What does BioAtla Inc do?

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.